Is Apple the Teflon Tech Stock? And the Latest Moves in the Weight Loss Drug Space 6/26/23
CNBC's "Fast Money"
00:00
The Economic Benefits of Early Cycle Drugs
A lot of these drugs are probably off patent already, so they're not big money makers necessarily. Majara was from Lilly is just approved last year in Type II diabetes and could be formally approved in obesity this fall. Jeff: You don't think there's any impact on other drug pipelines, like cholesterol, drugs, heart drugs, et cetera, until- A lot of those are generic.
Play episode from 34:16
Transcript
